Sydney, June 20, 2026, 05:07 (AEST)
- Cochlear finished Friday at A$118.14, gaining 3.37% for the day. Shares rose each session this week.
- The shares finished the week up 13.9%. That came as the S&P/ASX 200 fell 0.92% on Friday.
- Cochlear has bounced but still trades roughly 55% under its late 2025 closing level of A$260.66.
Cochlear Ltd shares finished up 3.37% at A$118.14 on Friday, closing out a five-day rally. The stock was at A$103.75 last week. The Australian market is shut for the weekend.
Healthcare stocks outperformed on a choppy day for Australian shares. The S&P/ASX 200 fell 82.4 points to 8,828.7 in the last session. Only three sectors finished higher, with healthcare among them. CSL surged 7.62%. Cochlear saw gains as well, likely riding renewed interest in healthcare stocks that had dropped in recent weeks.
Cochlear shares jumped with no new price-sensitive update behind the move. The last significant operating disclosure from the company was an earnings downgrade on April 22. The only other recent filing was a substantial-holder notice lodged June 9. Around A$224 million worth of Cochlear stock traded hands on Friday, putting it in the top 20 ASX stocks by value.
Valuations now look tricky. UBS has kept a Neutral call and a A$106 target. Morningstar’s Lochlan Halloway stuck with his fair-value number at A$110. The stock ended Friday 11.5% over the UBS target, and 7.4% up on Morningstar’s. Halloway said they were “more optimistic than the market about the resilience of cochlear implant demand,” citing rollout of the Nucleus Nexa and sales in emerging markets to boost growth after fiscal 2027. Ubs
Cochlear dropped its fiscal 2026 underlying net-profit forecast in April. The company now sees profit at A$290 million to A$330 million, down from the previous A$435 million to A$460 million range. Cochlear also projected second-half sales growth at 2% to 6% in constant currency. CEO Dig Howitt said then, “We remain confident of our market leadership,” mentioning the Nexa implant system’s adoption.
The downgrade sent shares down a record 40.7% in one day to A$99.58. At Friday’s close, the stock is about 19% higher than that post-downgrade low, so there’s been some recovery, but not a full return. It’s still well below its price at the start of 2026.
Cochlear’s rebound still has cracks. The company faces soft developed-market implant demand, hospital limits, fewer hearing-aid referrals, and some Middle East order risk. UBS points to US payer pressure and execution issues in Western Europe. If delayed procedures stay off the books, then lower production, restructuring charges, and a stronger Australian dollar could hit margins and outlook again.
ASX trading resumes Monday, with the quarterly index rebalance set to take effect ahead of the open. There’s no move for Cochlear in this reshuffle. The company’s full-year report isn’t due until August 18. The question now is if Friday’s strong healthcare rotation keeps going without a fresh trigger from a company update.
